Frequency Therapeutics to Present at Upcoming Investor Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/20/2026

1. TGT
2. EL
3. SPY
4. BILL
5. MRK

6. MRNA
7. ADI
8. LOW
9. TJX
10. DE

Get Alerts FREQ Hot Sheet

Price: $0.30 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

WOBURN, Mass.--(BUSINESS WIRE)-- Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present a company overview at the Jefferies Virtual Healthcare Conference and participate in a “fireside chat” at the Goldman Sachs Annual Global Healthcare Conference. Details for each event are as follows:

Jefferies Virtual Healthcare Conference
Presentation, Thursday, June 4 at 9 a.m. EDT
Goldman Sachs Annual Healthcare Conference 2020
Fireside chat, Tuesday, June 9 at 10:30 a.m. EDT

A live webcast of both presentations can be accessed on the investor section of Frequency’s website, investors.frequencytx.com. A replay of each presentation will be posted on the Frequency website for at least 30 days following each event.

About Frequency Therapeutics
Frequency Therapeutics is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The Company’s progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies. The Company’s lead product candidate, FX-322, is designed to regenerate auditory hair cells to restore hearing function. In a FX-322 Phase 1/2 study, statistically significant and clinically meaningful improvements in key measures of hearing function in patients with sensorineural hearing loss were observed. FX-322 is being evaluated in an ongoing Phase 2a study. The Company also is evaluating additional diseases where its PCA approach could create functional tissue, including a discovery program in multiple sclerosis.

Headquartered in Woburn, Mass., Frequency has a license and collaboration agreement with Astellas Pharma Inc. for FX-322, for which it retains U.S. rights, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including The Scripps Research Institute, Cambridge Enterprises Limited, Massachusetts Eye and Ear, Partners Healthcare and the Massachusetts Institute of Technology. For more information, visit www.frequencytx.com and follow Frequency on Twitter @Frequencytx.